ARWR - ARROWHEAD PHARMACEUTICALS, INC.

QQQ $ 585.01 $ -14.20 (-2.37 %)

DIA $ 457.77 $ -3.66 (-0.79 %)

SPY $ 651.93 $ -10.10 (-1.52 %)

TLT $ 89.25 $ 0.35 (0.39 %)

GLD $ 374.77 $ -0.11 (-0.03 %)

Previous Close

$ 38.09

Open

$ 39.83

Bid

$ 38.17 x 100

Ask

$ 38.24 x 3

Day's Range

$ 37.18 - $ 39.90

52 Week Range

$ 9.57 - $ 43.69

Volume

3,559,214

Average Volume

Market Cap

5.27B

Beta (5Y Monthly)

$ 1.69

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-12-2025	03-31-2025	10-Q
3	02-10-2025	12-31-2024	10-Q
4	11-26-2024	09-30-2024	10-K
5	08-08-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	02-06-2024	12-31-2023	10-Q
8	11-29-2023	09-30-2023	10-K
9	08-07-2023	06-30-2023	10-Q
10	05-02-2023	03-31-2023	10-Q
11	02-06-2023	12-31-2022	10-Q
12	11-28-2022	09-30-2022	10-K
13	08-04-2022	06-30-2022	10-Q
14	05-10-2022	03-31-2022	10-Q
15	02-02-2022	12-31-2021	10-Q
16	11-22-2021	09-30-2021	10-K
17	08-05-2021	06-30-2021	10-Q
18	05-04-2021	03-31-2021	10-Q
19	02-04-2021	12-31-2020	10-Q
20	11-23-2020	09-30-2020	10-K
21	08-05-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	02-05-2020	12-31-2019	10-Q
24	11-25-2019	09-30-2019	10-K
25	08-05-2019	06-30-2019	10-Q
26	05-08-2019	03-31-2019	10-Q
27	02-07-2019	12-31-2018	10-Q
28	12-11-2018	09-30-2018	10-K
29	08-07-2018	06-30-2018	10-Q
30	05-08-2018	03-31-2018	10-Q
31	02-09-2018	12-31-2017	10-Q
32	12-12-2017	09-30-2017	10-K
33	08-03-2017	06-30-2017	10-Q
34	05-03-2017	03-31-2017	10-Q
35	02-06-2017	12-31-2016	10-Q
36	12-14-2016	09-30-2016	10-K
37	08-09-2016	06-30-2016	10-Q
38	05-10-2016	03-31-2016	10-Q
39	02-09-2016	12-31-2015	10-Q
40	12-14-2015	09-30-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Goldman Sachs Maintains Neutral on Arrowhe...
11/20/2025 12:44:42

Goldman Sachs analyst Andrea Tan maintains Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and raises the price target from $2...

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
11/19/2025 17:35:20

RBC Capital Maintains Outperform on Arrowh...
11/19/2025 15:58:37

RBC Capital analyst Luca Issi maintains Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and raises the price target from $4...

Chardan Capital Maintains Buy on Arrowhead...
11/19/2025 13:22:15

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

Piper Sandler Maintains Overweight on Arro...
11/19/2025 12:12:29

Piper Sandler analyst Edward Tenthoff maintains Arrowhead Pharma (NASDAQ:ARWR) with a Overweight and raises the price target...

fda-clears-arrowhead-pharmas-first-ever-home-injection-for-rare-fat-disorder

FDA Clears Arrowhead Pharma's First-Ever H...
11/18/2025 18:07:28

Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with ...

Trading Halt: Halt status updated at 12:10...
11/18/2025 17:10:04

Arrowhead Pharmaceuticals Receives FDA App...
11/18/2025 16:13:18

https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

Trading Halt: Halted at 11:06:46 a.m. ET -...
11/18/2025 16:06:50

Morgan Stanley Maintains Equal-Weight on A...
11/12/2025 17:12:48

Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma (NASDAQ:ARWR) with a Equal-Weight and raises the price target ...

crispr-therapeutics-investigational-gene-therapy-shows-promising-lipid-lowering-effects-in-early-trial

CRISPR Therapeutics' Investigational Gene ...
11/11/2025 14:50:51

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its...

HC Wainwright & Co. Reiterates Buy on Arro...
10/08/2025 10:20:12

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $80 p...

Arrowhead Pharmaceuticals Files To Begin P...
10/07/2025 11:34:04

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has filed a request for regulatory clearance to initiate ...

4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals

4 Biotechnology Stocks That Outshine In Mo...
09/29/2025 11:11:04

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

Arrowhead Sues Ionis Seeking Declaratory J...
09/11/2025 11:31:48

Arrowhead Pharma Files Request For Regulat...
09/10/2025 11:31:54

- In preclinical studies presented today at the RNA Leaders USA Congress 2025, investigational ARO-MAPT demonstrated potent an...

HC Wainwright & Co. Reiterates Buy on Arro...
09/02/2025 16:05:27

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $80 p...

air-lease-ionis-pharmaceuticals-arrowhead-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday

Air Lease, Ionis Pharmaceuticals, Arrowhea...
09/02/2025 14:41:45

Arrowhead Pharmaceuticals Inks Global Lice...
09/02/2025 11:32:42

Upon closing, Arrowhead will receive an upfront payment of $200 millionNovartis will receive an exclusive worldwide license to ...

Arrowhead Receives $100M Milestone From Sa...
08/13/2025 20:30:04

- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed...